Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016277676> ?p ?o ?g. }
- W2016277676 endingPage "302" @default.
- W2016277676 startingPage "298" @default.
- W2016277676 abstract "No medical intervention has such an unambiguous track record of preventing morbidity and mortality from infectious diseases than that of vaccines. 1 Plotkin SA Vaccines, the fourth century. Clin Vacc Immunol. 2009; 16: 1709-1719 Crossref PubMed Scopus (167) Google Scholar The type of vaccine-preventable diseases ranges from the acute (eg, measles or meningitis) to the chronic (eg, liver and cervical cancers). Further reduction of deaths and disability from infections remains a major challenge. Few would deny that there is a moral imperative to make vaccines widely available on an equitable basis, but governments are frustratingly slow to grasp a different and compelling argument: vaccines create wealth. 2 Bloom DE Canning D Weston M The value of vaccination. World Economics. 2010; 6: 15-19 Google Scholar , 3 Bärnighausen T Bloom DE Canning D et al. Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine. Vaccine. 2011; 29: 2371-2380 Crossref PubMed Scopus (65) Google Scholar Richard Moxon: a virtuoso of vaccinologyAs subjects for profiles go, Richard Moxon is a touch intimidating. Described by no less an authority than Sir Gustav Nossal as an “Olympian figure in the world of paediatric vaccinology”, and hailed by Rino Rappouli as “a pioneer of the molecular mechanisms of bacterial pathogenesis, and the first one to link them to clinical practice, vaccine development, and public health”, Moxon's career defines what it is to be a clinician–scientist. So it was a relief to find that, in person, the Richard Moxon who emerges from the shadow of his reputation is as affable and engaging a man as you could hope to meet. Full-Text PDF The next decade of vaccines: societal and scientific challengesVaccines against microbial diseases have improved the health of millions of people. In the next decade and beyond, many conceptual and technological scientific advances offer extraordinary opportunities to expand the portfolio of immunisations against viral and bacterial diseases and to pioneer the first vaccines against human parasitic and fungal diseases. Scientists in the public and private sectors are motivated as never before to bring about these innovations in immunisation. Many societal factors threaten to compromise realisation of the public health gains that immunisation can achieve in the next decade and beyond—understanding these factors is imperative. Full-Text PDF Vaccine discovery and translation of new vaccine technologyAn unprecedented increase in new vaccine development has occurred over the past three decades. This activity has resulted in vaccines that protect against an increased range of vaccine-preventable diseases, vaccines that reduce the number of required injections, and vaccines with improved safety and purity. New methods of discovery, such as reverse vaccinology, structural biology, and systems biology, promise new vaccines for different diseases and efficient development pathways for these vaccines. Full-Text PDF Vaccine production, distribution, access, and uptakeFor human vaccines to be available on a global scale, complex production methods, meticulous quality control, and reliable distribution channels are needed to ensure that the products are potent and effective at the point of use. The technologies used to manufacture different types of vaccines can strongly affect vaccine cost, ease of industrial scale-up, stability, and, ultimately, worldwide availability. The complexity of manufacturing is compounded by the need for different formulations in different countries and age-groups. Full-Text PDF The future of immunisation policy, implementation, and financingVaccines have already saved many lives and they have the potential to save many more as increasingly elaborate technologies deliver new and effective vaccines against both infectious diseases—for which there are currently no effective licensed vaccines—such as malaria, tuberculosis, and HIV and non-infectious diseases such as hypertension and diabetes. However, these new vaccines are likely to be more complex and expensive than those that have been used so effectively in the past, and they could have a multifaceted effect on the disease that they are designed to prevent, as has already been seen with pneumococcal conjugate vaccines. Full-Text PDF Addressing the vaccine confidence gapVaccines—often lauded as one of the greatest public health interventions—are losing public confidence. Some vaccine experts have referred to this decline in confidence as a crisis. We discuss some of the characteristics of the changing global environment that are contributing to increased public questioning of vaccines, and outline some of the specific determinants of public trust. Public decision making related to vaccine acceptance is neither driven by scientific nor economic evidence alone, but is also driven by a mix of psychological, sociocultural, and political factors, all of which need to be understood and taken into account by policy and other decision makers. Full-Text PDF" @default.
- W2016277676 created "2016-06-24" @default.
- W2016277676 creator A5000469885 @default.
- W2016277676 creator A5027270405 @default.
- W2016277676 creator A5042027098 @default.
- W2016277676 creator A5044744240 @default.
- W2016277676 creator A5070211508 @default.
- W2016277676 creator A5079512093 @default.
- W2016277676 creator A5080005270 @default.
- W2016277676 creator A5082599575 @default.
- W2016277676 date "2011-07-01" @default.
- W2016277676 modified "2023-09-23" @default.
- W2016277676 title "A call to action for the new decade of vaccines" @default.
- W2016277676 cites W1983465488 @default.
- W2016277676 cites W1996682693 @default.
- W2016277676 cites W1997246404 @default.
- W2016277676 cites W2005651912 @default.
- W2016277676 cites W2012733893 @default.
- W2016277676 cites W2013164443 @default.
- W2016277676 cites W2036188801 @default.
- W2016277676 cites W2058685418 @default.
- W2016277676 cites W2085243765 @default.
- W2016277676 cites W2120800931 @default.
- W2016277676 cites W2121369371 @default.
- W2016277676 cites W2122718880 @default.
- W2016277676 cites W2144343331 @default.
- W2016277676 cites W2144983829 @default.
- W2016277676 cites W2146585051 @default.
- W2016277676 cites W2155239890 @default.
- W2016277676 doi "https://doi.org/10.1016/s0140-6736(11)60766-6" @default.
- W2016277676 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21664682" @default.
- W2016277676 hasPublicationYear "2011" @default.
- W2016277676 type Work @default.
- W2016277676 sameAs 2016277676 @default.
- W2016277676 citedByCount "33" @default.
- W2016277676 countsByYear W20162776762012 @default.
- W2016277676 countsByYear W20162776762013 @default.
- W2016277676 countsByYear W20162776762014 @default.
- W2016277676 countsByYear W20162776762015 @default.
- W2016277676 countsByYear W20162776762016 @default.
- W2016277676 countsByYear W20162776762018 @default.
- W2016277676 countsByYear W20162776762019 @default.
- W2016277676 countsByYear W20162776762020 @default.
- W2016277676 countsByYear W20162776762021 @default.
- W2016277676 countsByYear W20162776762023 @default.
- W2016277676 crossrefType "journal-article" @default.
- W2016277676 hasAuthorship W2016277676A5000469885 @default.
- W2016277676 hasAuthorship W2016277676A5027270405 @default.
- W2016277676 hasAuthorship W2016277676A5042027098 @default.
- W2016277676 hasAuthorship W2016277676A5044744240 @default.
- W2016277676 hasAuthorship W2016277676A5070211508 @default.
- W2016277676 hasAuthorship W2016277676A5079512093 @default.
- W2016277676 hasAuthorship W2016277676A5080005270 @default.
- W2016277676 hasAuthorship W2016277676A5082599575 @default.
- W2016277676 hasConcept C138816342 @default.
- W2016277676 hasConcept C142724271 @default.
- W2016277676 hasConcept C166957645 @default.
- W2016277676 hasConcept C17744445 @default.
- W2016277676 hasConcept C187212893 @default.
- W2016277676 hasConcept C199539241 @default.
- W2016277676 hasConcept C203014093 @default.
- W2016277676 hasConcept C22070199 @default.
- W2016277676 hasConcept C2776438120 @default.
- W2016277676 hasConcept C2778627824 @default.
- W2016277676 hasConcept C2779473830 @default.
- W2016277676 hasConcept C512399662 @default.
- W2016277676 hasConcept C71924100 @default.
- W2016277676 hasConcept C83867959 @default.
- W2016277676 hasConcept C95457728 @default.
- W2016277676 hasConceptScore W2016277676C138816342 @default.
- W2016277676 hasConceptScore W2016277676C142724271 @default.
- W2016277676 hasConceptScore W2016277676C166957645 @default.
- W2016277676 hasConceptScore W2016277676C17744445 @default.
- W2016277676 hasConceptScore W2016277676C187212893 @default.
- W2016277676 hasConceptScore W2016277676C199539241 @default.
- W2016277676 hasConceptScore W2016277676C203014093 @default.
- W2016277676 hasConceptScore W2016277676C22070199 @default.
- W2016277676 hasConceptScore W2016277676C2776438120 @default.
- W2016277676 hasConceptScore W2016277676C2778627824 @default.
- W2016277676 hasConceptScore W2016277676C2779473830 @default.
- W2016277676 hasConceptScore W2016277676C512399662 @default.
- W2016277676 hasConceptScore W2016277676C71924100 @default.
- W2016277676 hasConceptScore W2016277676C83867959 @default.
- W2016277676 hasConceptScore W2016277676C95457728 @default.
- W2016277676 hasIssue "9788" @default.
- W2016277676 hasLocation W20162776761 @default.
- W2016277676 hasLocation W20162776762 @default.
- W2016277676 hasOpenAccess W2016277676 @default.
- W2016277676 hasPrimaryLocation W20162776761 @default.
- W2016277676 hasRelatedWork W1976088484 @default.
- W2016277676 hasRelatedWork W2427822974 @default.
- W2016277676 hasRelatedWork W2769011369 @default.
- W2016277676 hasRelatedWork W2769065473 @default.
- W2016277676 hasRelatedWork W3029331198 @default.
- W2016277676 hasRelatedWork W3108773685 @default.
- W2016277676 hasRelatedWork W3173381452 @default.
- W2016277676 hasRelatedWork W4385189433 @default.
- W2016277676 hasRelatedWork W4385247041 @default.